Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Michel

Showing results (191-200 of 318) with videos related to

Pageof 32
Sort By:
Scientific Reports|May 3, 2022
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance databaseLéa Hoisnard, Bénédicte Lebrun-Vignes, Sébastien Maury, et al.
Haematologica|May 2, 2020
Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international studyBruno Fattizzo, Marc Michel, Anna Zaninoni, et al.
British Journal of Haematology|September 15, 2017
A clinical risk score for pulmonary artery thrombosis during acute chest syndrome in adult patients with sickle cell diseaseAnaïs Winchenne, Jérôme Cecchini, Jean-François Deux, et al.
Lancet (London, England)|October 1, 2023
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trialCatherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, et al.
Infectious Diseases (London, England)|October 16, 2018
Severe, non specific symptoms in non-typhoidal Salmonella infections in adult patients with sickle cell disease: a retrospective multicentre studyRomain Guery, Anoosha Habibi, Jean-Benoît Arlet, et al.
Platelets|May 2, 2023
Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched studyArthur Mageau, Bernard Bonnotte, Mikael Ebbo, et al.
American Journal of Hematology|December 17, 2017
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adultsAlexandra Serris, Zahir Amoura, Florence Canouï-Poitrine, et al.
British Journal of Haematology|May 11, 2022
Characteristics, management and outcome of acquired amegakaryocytic thrombocytopeniaAnais Roeser, Guillaume Moulis, Mikael Ebbo, et al.
Autoimmunity Reviews|December 29, 2015
Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysisGuillaume Moulis, Alexandra Audemard-Verger, Laurent Arnaud, et al.
American Journal of Hematology|October 4, 2016
A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)Marc Michel, Louis Terriou, Francoise Roudot-Thoraval, et al.
Pageof 32

Showing results (191-200 of 318) with videos related to

Sort By:
Pageof 32
Scientific Reports|May 3, 2022
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance databaseLéa Hoisnard, Bénédicte Lebrun-Vignes, Sébastien Maury, et al.
Haematologica|May 2, 2020
Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international studyBruno Fattizzo, Marc Michel, Anna Zaninoni, et al.
British Journal of Haematology|September 15, 2017
A clinical risk score for pulmonary artery thrombosis during acute chest syndrome in adult patients with sickle cell diseaseAnaïs Winchenne, Jérôme Cecchini, Jean-François Deux, et al.
Lancet (London, England)|October 1, 2023
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trialCatherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, et al.
Infectious Diseases (London, England)|October 16, 2018
Severe, non specific symptoms in non-typhoidal Salmonella infections in adult patients with sickle cell disease: a retrospective multicentre studyRomain Guery, Anoosha Habibi, Jean-Benoît Arlet, et al.
Platelets|May 2, 2023
Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched studyArthur Mageau, Bernard Bonnotte, Mikael Ebbo, et al.
American Journal of Hematology|December 17, 2017
Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adultsAlexandra Serris, Zahir Amoura, Florence Canouï-Poitrine, et al.
British Journal of Haematology|May 11, 2022
Characteristics, management and outcome of acquired amegakaryocytic thrombocytopeniaAnais Roeser, Guillaume Moulis, Mikael Ebbo, et al.
Autoimmunity Reviews|December 29, 2015
Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysisGuillaume Moulis, Alexandra Audemard-Verger, Laurent Arnaud, et al.
American Journal of Hematology|October 4, 2016
A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)Marc Michel, Louis Terriou, Francoise Roudot-Thoraval, et al.
Pageof 32